ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

10 links1 made here, not in the record14 judgments2 judges (the rules as one: Rule based)1 record change seen1 read an older version
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.govReplaced, or read an older versionMade here
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT06253871A Phase 1/2 Study ofIAM1363 in HER2 CancersIambic Therapeutics, IncPhase 1/Phase 2 · recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 17 · ClinicalTrials.gov record · Version of 2026-11-17Nov 17 · Rule based · Reading set asideReading set asideCONDITIONSBreast NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termAs of now · Rule based · Main conditionMain conditionCarcinoma, Non-Small-Cell L…The registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termStomach NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termNeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · General: a category, not a diseaseGeneral: a category, not a diseaseBrain NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termDRUGSINT012146Entry “IAM1363”, read by our name rule›Nov 18 · Rule based · TestedTestedCapecitabineEntry “Oral treatment with IAM1363 ca…›Nov 18 · Rule based · BackgroundBackgroundTrastuzumab deruxtecanEntry “Oral treatment with IAM1363 ca…›Nov 18 · Rule based · BackgroundBackgroundPembrolizumabEntry “Oral treatment with IAM1363 ca…›Nov 1 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundTrastuzumabMade here · Found by reading; no entr…›Nov 2 · Claude Opus 5.5 · Background · partnerNov 19 · Claude Opus 5.5 · Background · partnerBackground · partner

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Pembrolizumab

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Oral treatment with IAM1363 capsules or tablets, administered in combination with pembrolizumab +/- carboplatin +/- pemetrexed”the record gives no role
→judged=agrees
How the 2 judgments split100%of judgments with a known value say Background
Background · 2

All judgments on this study

WhenLinkJudgeDecisionState
Nov 1PembrolizumabClaude Opus 5.5BackgroundRead an older version
Nov 2Trastuzumabmade hereClaude Opus 5.5Background · partnerReplaced
Nov 14Breast NeoplasmsRule based · condition-kind ruleFinest filed termCurrent
Nov 14Carcinoma, Non-Small-Cell LungRule based · condition-kind ruleFinest filed termCurrent
Nov 14Stomach NeoplasmsRule based · condition-kind ruleFinest filed termCurrent
Nov 14NeoplasmsRule based · condition-kind ruleGeneral: a category, not a diseaseCurrent
Nov 14Brain NeoplasmsRule based · condition-kind ruleFinest filed termCurrent
Nov 17The record itselfClinicalTrials.gov recordVersion of 2026-11-17Record change
Nov 17The record itselfRule based · nightly checkReading set asideCurrent
Nov 18INT012146Rule based · role ruleTestedCurrent
Nov 18CapecitabineRule based · role ruleBackgroundCurrent
Nov 18Trastuzumab deruxtecanRule based · role ruleBackgroundCurrent
Nov 18PembrolizumabRule based · role ruleBackgroundCurrent
Nov 19Trastuzumabmade hereClaude Opus 5.5Background · partnerDraft
As of nowBreast NeoplasmsRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.

When a study changes after it was read

Every night, studies whose record changed are compared with the last reading. A change to sites or dates leaves the reading as it is; a reworded entry keeps it; a change to the treatments or conditions marks it to be read again.

Until it is read again, the page shows the last reading and says so.